Anindita Jessica, Tanaka Hiroki, Yamakawa Takuma, Sato Yuka, Matsumoto Chika, Ishizaki Kota, Oyama Taiji, Suzuki Satoko, Ueda Keisuke, Higashi Kenjirou, Moribe Kunikazu, Sasaki Kasumi, Ogura Yumika, Yonemochi Etsuo, Sakurai Yu, Hatakeyama Hiroto, Akita Hidetaka
Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba Aramaki, Aoba-ku, Sendai City 980-8578, Miyagi, Japan.
Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba City 260-0856, Chiba, Japan.
Pharmaceutics. 2024 Jan 26;16(2):181. doi: 10.3390/pharmaceutics16020181.
RNA vaccines are applicable to the treatment of various infectious diseases via the inducement of robust immune responses against target antigens by expressing antigen proteins in the human body. The delivery of messenger RNA by lipid nanoparticles (LNPs) has become a versatile drug delivery system used in the administration of RNA vaccines. LNPs are widely considered to possess adjuvant activity that induces a strong immune response. However, the properties of LNPs that contribute to their adjuvant activity continue to require clarification. To characterize the relationships between the lipid composition, particle morphology, and adjuvant activity of LNPs, the nanostructures of LNPs and their antibody production were evaluated. To simply compare the adjuvant activity of LNPs, empty LNPs were subcutaneously injected with recombinant proteins. Consistent with previous research, the presence of ionizable lipids was one of the determinant factors. Adjuvant activity was induced when a tiny cholesterol assembly (cholesterol-induced phase, ChiP) was formed according to the amount of cholesterol present. Moreover, adjuvant activity was diminished when the content of cholesterol was excessive. Thus, it is plausible that an intermediate structure of cholesterol (not in a crystalline-like state) in an intra-particle space could be closely related to the immunogenicity of LNPs.
Acc Chem Res. 2022-1-4
Expert Opin Drug Deliv. 2023-1
J Control Release. 2022-7
Int J Biol Macromol. 2020-11-15
Int J Nanomedicine. 2021
Nano Lett. 2020-5-12
Methods Mol Biol. 2025
Vaccines (Basel). 2025-8-20
Vaccines (Basel). 2025-4-28
Nat Commun. 2025-5-3
Vaccines (Basel). 2024-5-15
Mol Ther Methods Clin Dev. 2023-6-12
Vaccines (Basel). 2023-3-14
Adv Healthc Mater. 2023-6
Int J Mol Sci. 2023-1-31
Mol Ther Nucleic Acids. 2022-8-4